147 related articles for article (PubMed ID: 36300882)
1. An Engineered IgG-VHH Bispecific Antibody against SARS-CoV-2 and Its Variants.
Chi H; Wang L; Liu C; Cheng X; Zheng H; Lv L; Tan Y; Zhang N; Zhao S; Wu M; Luo D; Qiu H; Feng R; Fu W; Zhang J; Xiong X; Zhang Y; Zu S; Chen Q; Ye Q; Yan X; Hu Y; Zhang Z; Yan R; Yin J; Lei P; Wang W; Lang G; Shao J; Deng Y; Wang X; Qin C
Small Methods; 2022 Dec; 6(12):e2200932. PubMed ID: 36300882
[TBL] [Abstract][Full Text] [Related]
2. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
[TBL] [Abstract][Full Text] [Related]
3. Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants.
Kim JW; Heo K; Kim HJ; Yoo Y; Cho HS; Jang HJ; Lee HY; Ko IY; Woo JR; Cho YB; Lee JH; Yang HR; Shin HG; Choi HL; Hwang K; Kim S; Kim H; Chun K; Lee S
Antiviral Res; 2023 Apr; 212():105576. PubMed ID: 36870394
[TBL] [Abstract][Full Text] [Related]
4. Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth.
Ku Z; Xie X; Lin J; Gao P; Wu B; El Sahili A; Su H; Liu Y; Ye X; Tan EY; Li X; Fan X; Goh BC; Xiong W; Boyd H; Muruato AE; Deng H; Xia H; Zou J; Kalveram BK; Menachery VD; Zhang N; Lescar J; Shi PY; An Z
Nat Commun; 2022 Sep; 13(1):5552. PubMed ID: 36138032
[TBL] [Abstract][Full Text] [Related]
5. IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern.
Chang MR; Tomasovic L; Kuzmina NA; Ronk AJ; Byrne PO; Johnson R; Storm N; Olmedillas E; Hou YJ; Schäfer A; Leist SR; Tse LV; Ke H; Coherd C; Nguyen K; Kamkaew M; Honko A; Zhu Q; Alter G; Saphire EO; McLellan JS; Griffiths A; Baric RS; Bukreyev A; Marasco WA
Nat Commun; 2022 Oct; 13(1):5814. PubMed ID: 36192374
[TBL] [Abstract][Full Text] [Related]
6. Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants.
Li Q; Humphries F; Girardin RC; Wallace A; Ejemel M; Amcheslavsky A; McMahon CT; Schiller ZA; Ma Z; Cruz J; Dupuis AP; Payne AF; Maryam A; Yilmaz NK; McDonough KA; Pierce BG; Schiffer CA; Kruse AC; Klempner MS; Cavacini LA; Fitzgerald KA; Wang Y
Front Immunol; 2022; 13():995412. PubMed ID: 36172366
[TBL] [Abstract][Full Text] [Related]
7. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
[TBL] [Abstract][Full Text] [Related]
8. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo.
Hanke L; Das H; Sheward DJ; Perez Vidakovics L; Urgard E; Moliner-Morro A; Kim C; Karl V; Pankow A; Smith NL; Porebski B; Fernandez-Capetillo O; Sezgin E; Pedersen GK; Coquet JM; Hällberg BM; Murrell B; McInerney GM
Nat Commun; 2022 Jan; 13(1):155. PubMed ID: 35013189
[TBL] [Abstract][Full Text] [Related]
9. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice.
De Gasparo R; Pedotti M; Simonelli L; Nickl P; Muecksch F; Cassaniti I; Percivalle E; Lorenzi JCC; Mazzola F; Magrì D; Michalcikova T; Haviernik J; Honig V; Mrazkova B; Polakova N; Fortova A; Tureckova J; Iatsiuk V; Di Girolamo S; Palus M; Zudova D; Bednar P; Bukova I; Bianchini F; Mehn D; Nencka R; Strakova P; Pavlis O; Rozman J; Gioria S; Sammartino JC; Giardina F; Gaiarsa S; Pan-Hammarström Q; Barnes CO; Bjorkman PJ; Calzolai L; Piralla A; Baldanti F; Nussenzweig MC; Bieniasz PD; Hatziioannou T; Prochazka J; Sedlacek R; Robbiani DF; Ruzek D; Varani L
Nature; 2021 May; 593(7859):424-428. PubMed ID: 33767445
[TBL] [Abstract][Full Text] [Related]
10. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
Wu X; Cheng L; Fu M; Huang B; Zhu L; Xu S; Shi H; Zhang D; Yuan H; Nawaz W; Yang P; Hu Q; Liu Y; Wu Z
Cell Rep; 2021 Oct; 37(3):109869. PubMed ID: 34644535
[TBL] [Abstract][Full Text] [Related]
11. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
12. A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variants.
Kim JW; Kim HJ; Heo K; Lee Y; Jang HJ; Lee HY; Park JW; Cho YB; Lee JH; Shin HG; Yang HR; Choi HL; Shim HB; Lee S
Front Immunol; 2023; 14():1271508. PubMed ID: 37822941
[TBL] [Abstract][Full Text] [Related]
13. Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses.
Lim HT; Kok BH; Lim CP; Abdul Majeed AB; Leow CY; Leow CH
Biomed Eng Adv; 2022 Dec; 4():100054. PubMed ID: 36158162
[TBL] [Abstract][Full Text] [Related]
14. Antibody cocktail effective against variants of SARS-CoV-2.
Liang KH; Chiang PY; Ko SH; Chou YC; Lu RM; Lin HT; Chen WY; Lin YL; Tao MH; Jan JT; Wu HC
J Biomed Sci; 2021 Nov; 28(1):80. PubMed ID: 34814920
[TBL] [Abstract][Full Text] [Related]
15. An engineered bispecific human monoclonal antibody against SARS-CoV-2.
Li Z; Li S; Zhang G; Peng W; Chang Z; Zhang X; Fan Z; Chai Y; Wang F; Zhao X; Li D; Zhang R; He Z; Zou W; Xu K; Lei W; Liu P; Hao J; Zhang J; Sun L; Wu G; Tan S; Gao GF; Gao F; Wu Y
Nat Immunol; 2022 Mar; 23(3):423-430. PubMed ID: 35228696
[TBL] [Abstract][Full Text] [Related]
16. XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants.
Vanhove B; Marot S; So RT; Gaborit B; Evanno G; Malet I; Lafrogne G; Mevel E; Ciron C; Royer PJ; Lheriteau E; Raffi F; Bruzzone R; Mok CKP; Duvaux O; Marcelin AG; Calvez V
Front Immunol; 2021; 12():761250. PubMed ID: 34868003
[TBL] [Abstract][Full Text] [Related]
17. Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron.
Casasnovas JM; Margolles Y; Noriega MA; Guzmán M; Arranz R; Melero R; Casanova M; Corbera JA; Jiménez-de-Oya N; Gastaminza P; Garaigorta U; Saiz JC; Martín-Acebes MÁ; Fernández LÁ
Front Immunol; 2022; 13():863831. PubMed ID: 35547740
[TBL] [Abstract][Full Text] [Related]
18. A VHH single-domain platform enabling discovery and development of monospecific antibodies and modular neutralizing bispecifics against SARS-CoV-2 variants.
Yang ML; Yuan TZ; Chan KY; Ding L; Han Z; Franco H; Holliday C; Kannan S; Davidson E; Doranz BJ; Chandran K; Miller EH; Plante JA; Weaver SC; Cho E; Kailasan S; Marsalek L; Giang H; Abdiche Y; Sato AK
Antib Ther; 2024 Apr; 7(2):164-176. PubMed ID: 38933534
[TBL] [Abstract][Full Text] [Related]
19. An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant.
Yuan M; Zhu Y; Liu G; Wang Y; Wang G; Zhang G; Ye L; Qian Z; Liu P
One Health Adv; 2023; 1(1):12. PubMed ID: 37521533
[TBL] [Abstract][Full Text] [Related]
20. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
